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ABSTRACT – Background and Objectives: The search for accurate biomarkers in Alzheimer
Disease (AD), on of the most devastating neurodegenerative diseases, remains essential to
enable an early prognosis and diagnosis of the disease and to provide more efficient ther-
apeutic strategies.
A wide variety of potential biomarkers are has been identified by neuroimaging tech-
niques and by the analysis of fluid samples, such as cerebrospinal fluid (CSF) or blood.
Recently, a growing number of studies are focused on the discovery of reliable blood-
based biomarkers in blood, especially in the prodromal stage of AD, which can predict the
conversion of asymptomatic cases to AD demented cases.
In this review, the latest challenges in the search for accurate biomarkers of AD is re-
vised, in particular, an update in blood-based biomarkers is described in depth.
Conclusions: Finally, the close link among AD and other neurodegenerative diseases is
discussed, mainly based on the last discovered mutation, the chromosome 9 open reading
frame 72, C9ORF72.
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Challenges in the discovery
of potential biomarkers in
Alzheimer Disease
To date there are no effective therapies to
preserve normal brain function in potential
future Alzheimer’s disease (AD) patients.
The absence of reliable biomarkers to iden-
tify cognitive normal individuals that will
become early-stage AD patients support this
fact. Therefore, this overlap between de-
mented and non-demented population has
limited the diagnostic accuracy of the current
known biomarkers for AD. Due to the fact
that neurological processes that finally re-
sult in dementia are assumed to be actively
long before the first symptoms appear, the
availability of diagnostic biomarkers could
make a preclinical diagnostic testing and an
early treatment of AD possible.
A great variety of biomarkers of AD has
been described using different approaches
(Table 1). As Figure 1 shows, different strate-
gies can be studied along AD progression
for a better understanding of the disease and
to enable an accurate identification of po-
tential AD biomarkers. Currently, the most
studied methods to identify markers of mild
cognitive impairment (MCI) and AD are neu-
roimaging and molecular techniques based
on cerebrospinal fluid (CSF). A systematic
search on PubMed and Scopus databases was
performed to find the most relevant studies
and review papers. The key words used for
this purpose were: “Alzheimer’s disease”,
“Mild Cognitive Impairment”, “biomarkers”,
“blood”, “neuroimaging” and “neurodegen-
erative diseases” in various combinations.
The articles selected were published in Eng-
lish from 2004 to 2015.
Neuroimaging is a non-invasive technique
which monitors brain regions and allows the
subsequent identification and quantification
of diagnostic and candidate biomarkers of
dementia progression1. Magnetic resonance
imaging (MRI) is the most widely used neu-
roimaging technique to investigate brain
changes and neurodegeneration. Several lon-
gitudinal studies using MRI have been con-
ducted with positive results2,3. After follow-
up assessments, these studies supported that
MRI is a valuable biomarker to predict early
conversion to dementia in patients with MCI.
In particular, a maximum value of 1.61 for
the occipital cortex N-acetylaspartate / crea-
tine ratio was useful to predict dementia at
100% sensitivity and 75% specificity, yield-
ing a positive predictive value of 83% and a
negative predictive value of 100%2. The same
ratio in the posteromedial bilateral parietal
cortex could enable a predicted conversion
rate to probable AD with a sensitivity of
74.1% and a specificity of 83.7%3. Further-
more, MRI is capable of measuring both re-
gional and global brain atrophy, determining
the extent of the brain degeneration in pa-
tients with dementia4,5. Based on this, several
groups have proposed the rate of hippocam-
pal atrophy in MCI patients as a predictor for
the conversion to AD6,7. Other measurements
by MRI, like cortical thickness, have been
performed in amnestic MCI (aMCI) patients,
which have the highest conversion rate to
AD8. However, these measurements alone
could not distinguish among aMCI subtypes
and controls. White matter (WM) and grey
matter (GM) have also been studied using
MRI, which showed lower volumes of WM
and GM in different brain regions in MCI pa-
tients who converted to AD9. A more sensi-
tive to microscope WM changes technique is
diffusion tension imaging (DTI). Nir et al.
(2013) showed widespread diffusivity dis-
ruptions associated with neuropsychological
and cognitive deficits in specific tracts that
passed through the temporal lobe and poste-
rior brain regions in AD and MCI patients10.
Despite MRI is widely used for AD, the ac-
curacy of MRI as biomarker of early AD
generally reaches an accuracy of 80%11, what
encourages the search of better biomarkers
and more accurate diagnostic tools. Several
studies demonstrated that the accuracy to
predict conversion from MCI to AD in MRI
was enhanced when combined with positron
emission tomography (PET)12,13, where the
best brain region for MRI and PET was the
temporal cortex13.
Currently, PET is one of the most sensitive
tests for and early AD detection comparing to
other biomarkers, such as CSF measures of
Aβ-42 or Aβ-42/tau14,15. However, its high
cost hampers its regular clinical use. PET
can determine the presence or activity of pro-
teins, enzymes and metabolic pathways in-
volved in dementia16, and it has been used for
prediction of progression from MCI to AD
showing promising results. Particularly, 11C-
Pittsburgh compound B positron emission
tomography (11C-PIB-PET) may play a role
in stratifying patients with MCI into risk lev-
els for developing AD, yielding a 83.3% to
100% sensitivity and a 41.1% to 100% speci-
ficity for predicting conversion to AD17. In
addition, in a recent study, fluorodeoxyglu-
cose PET (FDG-PET) images were used to
investigate MCI to AD conversion at differ-
ent prodromal stages18. The results showed
that MCI to AD conversion can be predicted
as early as 24 months prior to conversion. An-
other molecular imaging technique suggested
as a predictor of conversion to dementia is
proton magnetic resonance spectroscopy (1H-
MRS)19. In particular, five metabolite ratios
were calculated in four different brain re-
gions in MCI patients, but only mI/CR ratio
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Figure 1. Overview of the main categories of biomarkers that can be identified along AD progression. Biomarkers of
exposure can be indicative of disease risk factors, while biomarkers of disease are useful in the screening (prognostic
biomarkers), in the early stages of the disease (diagnostic biomarkers) and in the monitoring of disease progression.
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(myo-inositol/creatine ratio) in the cortical
area of right parietal lobe in MCI subjects
predicted the conversion to AD with sensi-
tivity 70% and specificity 85%.
Recent studies suggest the combination of
data for an accurate diagnose and prediction
of dementia progression. A longitudinal study
evaluated a multivariate method combining
morphometric variables in patients with MCI,
AD and controls20. This study suggested an
index based on temporal evolution of brain
degeneration using MRI, combined with
other longitudinal information could be a re-
liable method to identify preclinical AD pa-
tients, as well as to predict conversion from
MCI to AD. Other studies have supported
the combination of data from neuroimaging
to obtain more accurate diagnostic and pre-
dictive tools21,22. Particularly, a study com-
bined data from neuroimaging for tracking
dementia progression by proposing a method
based on support vector machines. The re-
sults obtained showed a higher prediction for
progression from MCI to AD, and a better
differentiation between AD and healthy pa-
tients when considering the brain as a whole,
rather than separate brain regions22.
During the last decade, neuroimaging has
been shown as a potential tool for diagnosis
and prediction of AD; however most of the
AD biomarkers described are measured in
CSF. Although CSF biomarkers combined
can optimally discriminate AD patients from
controls, as well as prognosticate conversion
from MCI to AD, they are not suitable for
distinguishing AD from other dementias23.
Over the past two decades, three CSF bio-
markers have been widely studied: amyloid β
peptide 42 (Aβ-42), total tau protein (T-tau)
and hyperphosphorilated tau protein (P-tau),
which have been shown to be reliable mark-
ers for early diagnosis of AD and prediction
of disease progression24,25.
Many studies have shown that AD patho-
physiological processes are characterized by
decreased amyloid concentrations, increased
tau concentrations or increased tau/amyloid
concentrations16,26-28. As an example, a 4-
year follow-up study showed that all MCI pa-
tients with levels of the three CSF markers
abnormally altered at baseline developed AD
dementia within one year26. Interestingly,
Buchhave et al. (2012) found decreased Aβ-
42 levels in MCI patients at an early stage, be-
fore conversion to AD dementia. In contrast,
levels of T-tau and P-tau were found increased
at a later stage27,29. Moreover, Aβ-42/P-tau ra-
tio predicted the conversion to AD dementia
within 9.2 years with a sensitivity and speci-
ficity of 0.88 and 0.90, respectively27. Other
studies have also determined Aβ-42 as an
early marker, followed by tau proteins28,30.
Aβ-42 has also been suggested as a trustwor-
thy marker for distinguishing among MCI,
AD and other dementias31,32. In this sense,
lower CSF Aβ-42 levels were found in AD pa-
tients compared to those measured in MCI
subjects and with other dementias. Regarding
P-tau separately, a meta-analysis of 51 stud-
ies based on MCI and AD patients concluded
that CSF P-tau levels were a precise diag-
nostic biomarker for MCI and AD, as well as
for progression of MCI. Conversely, CSF P-
tau levels were less adequate in distinguishing
AD from other dementias33.
In addition, accuracy of these CSF biomar -
kers can be improved when combining with
other CSF proteins, as Perrin et al. (2011)
demonstrated. After a CSF proteomic study,
they suggested four novel CSF markers for
MCI and AD (NrCAM, YKL-40, chromo-
granin A, carnosinase I) that enhanced diag-
nostic accuracy of Aβ-42 and P-tau for distin-
guishing groups with mild, very mild cognitive
impairment or no dementia34. A recent study
also identified changes in several CSF proteins
between controls and AD subjects, and sug-
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gested four proteins as potential progression
biomarkers (amyloid precursor protein, neu-
ronal pentraxin receptor, NrCAM and chro-
mogranin A)35.
Although the current CSF biomarkers can
be considered accurate markers for diagnosis
and prediction of AD (Table 1), there are still
large variations in biomarker measurements
between studies, and between and within lab-
oratories36. Both CSF and neuroimaging bio-
markers have been proved to have valuable
diagnostic and prognostic capacity in AD.
Nevertheless, the combination of them, to-
gether with cumulative information from
clinical examination, could enhance their ac-
curacy in detecting MCI and AD patients in
early stages as well as the conversion to AD
that will allow an effective therapy before
the latest stage37. Hu et al. (2010) proposed
the use of a multi-analyze profiling to iden-
tify novel candidate biomarkers, included in
the RBM Human DiscoveryMAP™ panel,
which could help to improve the accuracy of
the established CSF markers38. The combi-
nation of CSF markers and cognitive tests,
such as Mini-Mental State Examination
(MMSE) and the clock drawing, has been
also suggested, as it showed to be signifi-
cantly better than these methods alone for
prediction of conversion from MCI to AD39.
Several studies assessed the predictive accu-
racy for the diagnosis and conversion to AD
when analyzing CSF markers together with
MRI and/or neuropsychological and func-
tional measures (NMs)40-43. The results de-
termined that combination of selected MRI,
CSF and/or NM features outperformed a sin-
gle modality of these features. Moreover,
combination of CSF, imaging, genetic and
cognitive markers and other methods has been
performed to measure both the temporal evo-
lution of AD29 and predict more accurately the
conversion from MCI to AD44 (Table 1).
Although the established biomarkers of
AD from CSF and neuroimaging are precise,
their clinical application has limitations due
to their invasiveness or high cost. This sup-
ports the need to find other easily available
and accessible biomarkers that make a diag-
nostic of early AD possible, and therefore, the
possibility to identify those susceptible indi-
viduals in order to apply an effective therapy
before the onset of the disease.
The search for reliable
blood-based biomarkers
The neurodegeneration presented in AD is
mainly characterized by the deposition of se-
nile plaques, composed of amyloid beta pep-
tide and neurofibrillary tangles of hyper-
phosphorylated tau protein, especially in the
hypocampus, amygdala and frontal cortex.
Dealing with the search of putative biomark-
ers of AD, an AD prodromal phase, identified
as MCI can be precisely the useful time-point
to test reliable biomarkers that can enable an
early and accurate prognosis and diagnosis of
the disease. The complexity of the pathogen-
esis of AD, which is not fully understood to
date, is caused by a synergy of risk factors and
the combination of current well-character-
ized biomarkers, from neuroimaging, genetic
to fluid biomarkers (Table 1), can improve
prognostic and diagnostic accuracy45.
Albeit neuroimaging tools have provided a
reliable early detection and differentiation of
AD, they still remain as a quite expensive di-
agnostic tool in many hospitals and clinical
centers. Conversely, the detection of CSF,
blood (plasma or serum) and urine biomarkers
could be also useful for the disease character-
ization, even at preclinical stage. Regarding
urine biomarkers, several biochemical mark-
ers have been described as potential bio-
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markers for dementia, such as the level of uri-
nary 3-hydroxypropyl mercapturic acid (3-
HPMA)/creatinine (Cre)46 and the level of
urinary Alzheimer-associated neuronal thread
protein (AD7c-NTP), which may be an im-
portant biomarker for an early diagnosis of
MCI47. Particularly, decreased levels in 3-
HPMA/Cre in urine correlated with increase
in Aβ40/42 in plasma in demented subjects46,
while increased levels of AD7c-NTP were
found in AD and MCI patients47. Neverthe-
less, the minimally invasive nature, possible
follow-up of patients, low risk and cost and
the possibility of screening healthy popula-
tion make the blood the first choice to ana-
lyze putative biomarkers. In spite of the low
sensitivity and specificity of blood biomark-
ers, the invasive sample collection by lumbar
puncture, which is needed in the analysis of
CSF samples, is less preferred than a wider
range of blood-based biomarkers study to
identify reliable biomarkers of prodromal
AD and AD dementia45,48. Interestingly,
blood-based proteomic search of biomarkers
in heterogeneous populations of individuals
supports an alteration of the blood proteome
in AD patients49.
Reliable biomarkers of prodromal AD and
AD dementia are essential for early AD de-
tection at preclinical stages. Since it is ex-
pected that the number of demented people
will exponentially increased in the next years
and taking into consideration the lack of an ef-
fective therapeutic approach for AD, the de-
tection of these reliable biomarkers could en-
able the treatment of asymptomatic patients
before the degeneration progresses severely.
At this step, the standardization of blood-
based biomarker studies for the improvement
of diagnosis, treatment and care of AD pa-
tients has become the ultimate goal of the
Standards for Alzheimer’s Research in Blood
biomarkers (STAR-B) working group48.
The advantages of blood tissue in the search
of reliable AD biomarkers compensate for
the limited detection of potential biomarkers
closely related to brain pathogenesis through
the blood brain barrier and the inevitably di-
lution of brain derived proteins and metabo-
lites in this tissue50. Among the biomarkers
studied in blood (plasma or serum), Aβ is the
most studied one, especially in plasma sam-
ples (Table 1). Abnormal production and ag-
gregation of Aβ isoforms is one of the earli-
est pathophysiological hallmarks that take
place in the brain, and they begin several
decades before the onset of clinical symp-
toms, triggering synaptic loss, neuronal death
and clinical dementia. As a consequence, the
monitoring of the amyloid processes in
asymptomatic subjects could be useful to se-
lect those at the prodromal stage that will
progress to AD51.
Although it remains under debate whether
plasma Aβ levels could be considered a reli-
able biomarker because of the controversial
published results, recent studies point out to a
decreased Aβ-42 / Aβ-40 ratio as a risk factor
to MCI conversion to AD, while other stud-
ies have suggested that increased Aβ-40 and
Aβ-42 plasma levels, simultaneously or sep-
arately, could play a role as putative bio-
markers of AD45,50,52,53. In particular, de-
creased levels of Aβ-42 or decreased Aβ-42
/ Aβ-40 ratio in aging could indicate a con-
version from a normal cognitive status to
MCI or AD54,55. Similarly, unaltered Aβ
plasma levels have also been found when
comparing AD patients and control cases50,56.
In addition, plasma Aβ levels have been
tested in different studies of correlation. As
an example, plasma Aβ levels did not correlate
with CSF Aβ levels. A multiplex immunoas-
say analysis in two independent cohorts of
patients showed unaltered levels of plasma
Aβ in incipient AD and a lack of corre lation of
Aβ-42 levels in CSF and plasma57,58. Howe -
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ver, positive although no significant correla-
tions were found between plasma Aβ levels
and plasma homocysteine50. More recently,
the sensitivity and specificity of plasma Aβ-
42 levels were significantly improved to 0.8
and 0.82 respectively, when combined plas -
ma Aβ-42 and tau protein levels and moni-
tored them with the use of immunomagnetic
reduction assays (IMR). This ultrahigh sen-
sitivity technology could make possible the
low detection limits for amyloids and tau pro-
tein (1-10 pg/ml). This improvement in the de-
tection of very low protein levels could enable
not only the differentiation of healthy cases and
AD patients, in both prodromal and dementia
phases, but it also allowed the identification of
the group of MCI cases due to AD59.
One of the largest prospective studies of
plasma Aβ levels and the risk of incident of
AD disease and dementia is the Framing-
ham Heart Study, which included more than
two thousand participants with a long period
of follow-up. The main results obtained in
this study suggested that lower plasma Aβ-42
and Aβ-40 levels preceded and were associ-
ated with the risk of incident AD and de-
mentia. In particular, low plasma Aβ-42 lev-
els were associated with higher risk of
incident AD and dementia, and significant as-
sociations between low plasma Aβ-42 levels
and Aβ-42 / Aβ-40 ratio were also found as-
sociated with higher risk of incident AD and
dementia51. In spite of the limitations of the
study, this work reinforced the potential role
of plasma Aβ levels as a useful biomarker for
preclinical AD and dementia. In accordance
with Framingham Heart Study, a previous
longitudinal study based on 2,454 patient
plasma samples from the Alzheimer’s Dis-
ease Neuroimaging Initiative study found rel-
atively strongest correlations between plasma
Aβ-42 levels and CSF p-tau181 / Aβ-42 ratio
in MCI patients, pointing out to the use of
plasma Aβ as a potential biomarker60. In re-
lation to plasma Aβ levels, it has been also
shown that an increase in oxidized lipopro-
tein receptor-related protein-1 (sLRP) could
lead to elevated levels of Aβ-40 and Aβ-42,
which re-entered the brain favoring the risk of
MCI and AD. In fact, high levels of oxidize
sLRP and free plasma Aβ-40 and Aβ-42 cor-
related significantly with CSF tau / Aβ-42 ra-
tios and reductions in MMSE scores61.
As above mentioned, other relevant bio-
markers in blood samples are serum or plasma
tau levels (Table 1). The main handicap in this
case remains in the increased levels of tau in
other pathologies, such as ischemic stroke or
traumatic brain injury, while in AD or MCI, tau
levels are difficult to detect. However, a recent
and more sensitive immunoassay methodol-
ogy can detect both normal and phosphory-
lated tau, suggesting that serum tau levels
could be useful in the identification of AD62.
Furthermore, recent studies support the po-
tential nature of AD biomarker of tau since a
fragment of tau in serum correlated with cog-
nitive function in a small clinical study. In con-
nection with this result, the existence of plasma
post-translational modifications (PTMs), called
neo-epitopes, are considered chemical modi-
fications that can prompt proteomic diversity.
Albeit protein PTMs can be reversible de-
pending on the nature of modification, the
identification and better understanding of
PTMs are essential to study the cellular and
molecular mechanisms involved under phys-
iological or pathological conditions. There-
fore, in relation to AD disease, PTM-based
biomarker could provide useful information
about the disease progression. The induction
of neuronal death in AD, in which tau is trun-
cated in a caspase dependent mechanism, can
generate pathological truncated protein
species, which could become staging bio-
markers that could enable the monitoring of
disease progression62.
Novel blood-based biomarkers for AD
(Table 1), such as circulating microRNA and
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a wide variety of plasma proteins and lipids
suggested by transcriptomic and lipidomic se-
quencing, support the use of peripheral blood
for unbiased screening to detect significant
preclinical alterations in AD patients, which
are reflected in the periphery that can be eas-
ily and minimally invasive analyzed49. In this
sense, the combination of several markers can
significantly improve the diagnostic accuracy.
Panels of serum biomarkers for inflammation,
homocysteine and cholesterol metabolism and
brain specific proteins have been evaluated,
yielding high accuracy, close to 90%, to dif-
ferentiate AD patients from control cases and
they also provided a useful tool to predict
MCI patients that later converted to AD pa-
tients50. As an example, some identified plas -
ma biomarkers are α2-macroglobulin, com-
plement factor H, homocysteine, cholesterol,
E4 isoform of apolipoprotein E, F2-iso-
prostanes, Aβ autoantibodies, apolipoprotein
A1, clusterin/apolipoprotein-J, isoprostane or
glycogen synthase kinase (GSK-3β)45,63-65.
Regarding calmodulin, this potential plasma
biomarker was found significantly upregu-
lated in MCI and AD patients with a sensitiv-
ity of 0.87 and a specificity of 0.82, suggest-
ing its possible role in the identification of
early stages in AD and in the discrimination
from other types of dementia66. Reduced phos-
pholipase A2 activity has also been suggested
as a risk marker for AD in subjects with
MCI67. Similarly, sphingomyelins and ce-
ramides could be predictive of memory im-
pairment and they could be useful for the on-
going AD pathology and progression in
asymptomatic cases68. Interestingly, very long
plasma ceramides were found altered in MCI,
and it has been suggested that they could pre-
dict memory and right hippocampal volume
loss among subjects with MCI69.
Moreover, 18 signaling proteins were iden-
tified in plasma with a 90% accuracy to dis-
tinguish patients who had MCI and progressed
to AD 2-6 years later. These signaling proteins
were related to changes in the periphery, the
central nervous system or both that were rel-
atively specific to AD and took place in the
first stages of disease process70. Similar stud-
ies dealing with protein-based multiplex bio-
marker data from control and AD patients
showed that serum protein-based biomarkers
improved their diagnostic accuracy when they
were combined with clinical information, such
as age, sex, education and APOE status71. A
more recent study have identified a panel of 10
plasma proteins associated with neuroimaging
measures of the disease that can predict dis-
ease conversion from MCI to AD within a
year of blood sampling72. Another recent study
based on isobaric tag (iTRAQ) and proteomic
methods, identified 30 plasma proteins, such
as afamin and immunoglobulin heavy con-
stant mu (IGHM), that could be potential bio-
markers for MCI and AD73.
The possibility to identify in blood an
Alzheimer’s biomarker phenotype could fa-
vor the diagnosis of early AD. The study not
only of the serum or plasma proteome but
also of the relationships among different sig-
naling proteins and intercellular communi-
cation factors could pave the way to new ap-
proaches for the search of AD biomarkers
suitable for an early prognosis and diagnosis
of the disease, and therefore for novel thera-
peutic strategies.
Common insights in AD and
other neurodegenerative
diseases
Regarding other neurodegenerative disor-
ders, there is an important clinical need to
identify and establish accurate biomarkers
for the classification of neurodegenerative
dementias, including AD, Parkinson disease
(PD), frontotemporal dementia (FTD) and
Amyotrophic Lateral Sclerosis (ALS), in
which several pathological pathways lead-
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ing to neurodegeneration are overlapped. A
frequent pathological characteristic impli-
cated in these disorders is the accumulation
and aggregation of abnormal or misfolded
proteins (amyloid-β in AD, α-synuclein in
PD, and TDP-43 in FTD and ALS)74. More-
over, common processes that modulate neu-
rodegeneration also include aberrant regula-
tion of apoptosis, uncontrolled activation of
autophagy, mytochondria dysfunction and
oxidative DNA damage74.
Concerning genetics, the GGGGCC hexa-
nucleotide repeat expansion intronic to chro-
mosome 9 open reading frame 72 (C9ORF72)
was first identified as a common genetic
cause of ALS and FTD75,76. Nevertheless,
recent studies about C9ORF72 have shown
this expansion involved in diverse molecular
mechanisms in other dementias, especially in
AD and PD, confirming the pathological in-
terrelationship between these diseases77-79.
In particular, two early-onset AD patients
were found to harbour C9ORF72 expansions
in a study regarding FTD genes80. Another
study concerning Caucasian families showed
C9ORF72 expansions (> 30 repeats) at a rate
of 0,76% in AD cases versus zero in controls,
supporting the notion that large C9ORF72 ex-
pansions have a considerable role in neurode-
generative diseases including AD81. In con-
trast, the allele frequency of C9ORF72 repeats
was estimated in ALS, frontotemporal lobar
degeneration (FTLD), AD and PD; however,
this expansion was only commonly found in
ALS and FTLD, but not in AD or PD82. In ac-
cordance to these results, no pathogenic ex-
pansions (< 30 repeats) of C9ORF72 were
found in either AD patients or controls83. In
the same study, as regards PD, it was sug-
gested the intermediate (≥ 7 repeats) repeat al-
lele in C9ORF72 as a risk factor for PD.
Despite the fact that C9ORF72 patholog-
ical repeats are not frequently found in AD or
PD, their presence in some cases supports the
simultaneity of diverse clinical and patho-
logical features between several neurode-
generative diseases. On the other hand, their
low frequency in AD and PD, compared to it
in ALS and FTD, could be a useful tool for
making a more precise diagnosis between
these dementias.
Given the pathological and clinical over-
lapping in diverse neurodegenerative disor-
ders, it is crucial to find potential and trust-
worthy biomarkers that allow developing an
accurate classifying method for an early di-
agnosis of neurodegenerative diseases, which
could make an early treatment for patients
possible. Regarding AD, the identified bio-
markers obtained from CSF and neuroimag-
ing have reached clinical applications and
their significant limitations in the disease
stage and dementia identification can be ac-
curately improved when they are combined in
tandem with blood-based biomarkers. Future
studies based on improved methodological
approaches will provide a better understand-
ing of the neurodegenerative progression of
the disease and they could undoubtedly pro-
mote more promising and effective thera-
peutic strategies for AD.
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